Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity

Haiming Chen, Eric Souther, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Ning Xu, James R. Berenson

Blood (2022) 140 (Supplement 1): 12460–12461.

https://doi.org/10.1182/blood-2022-167862

Published: 2022

Journal Articles

Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-Cells By Upregulating IFNγ and Gzmb

Haiming Chen, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Charles David Deighton, Ning Xu, James R. Berenson

Blood (2022) 140 (Supplement 1): 12459.

https://doi.org/10.1182/blood-2022-167768

Published: 2022

Journal Articles

The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients

Ning Xu, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Charles David Deighton, Haiming Chen, James R. Berenson

Blood (2022) 140 (Supplement 1): 12458.

https://doi.org/10.1182/blood-2022-167320

Published: 2022

Journal Articles

Evaluation of Repotrectinib's Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo

Haiming Chen, Eric Souther, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Ning Xu, James R. Berenson

Blood (2022) 140 (Supplement 1): 4213–4214.

https://doi.org/10.1182/blood-2022-169890

Published: 2022

Journal Articles

Dominant Expression of PVRIG and TIGIT Inhibitory Pathways in Bone Marrow of Multiple Myeloma Patients

Masha Frenkel, Zoya Alteber, Ning Xu, Mingjie Li, Haiming Chen, Gady Cojocaru, James R. Berenson, Eran Ophir

Blood (2021) 138 (Supplement 1): 4717.

https://doi.org/10.1182/blood-2021-148052

Published: 2021

Journal Articles

Anti-Myeloma Effects of Panobinostat in Combination with Duvelisib

Haiming Chen, Mingjie Li, Marissa Goldwater, Stacy Behare, Jasmin Cao, Cara Wallingford, Ava Hekmati, Rocky Levin, Eric Souther, Ning Xu, James R. Berenson

Blood (2021) 138 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2021-153983

Published: 2021

Journal Articles

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients

Samuel D. Stampfer, Marissa-Skye Goldwater, Bernard Sean S. Regidor, Scott Kristian Jew, Sean Elliott Bujarski, Haiming Chen, David Yashar, Ning Xu, Mingjie Li, Tracy Green, Eddie Fung, Elias Aquino, Regina Swift, Shahrooz Eshaghian, Aaron Feinstein, James R. Berenson

Blood (2021) 138 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2021-154287

Published: 2021

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ning Xu, PhD, Nicole Ng, BS, Mingjie Li, BS, Erin Yu, BS, Eric Sanchez, BA, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1824.

https://doi.org/10.1182/blood-2019-131047

Published: 2019

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4352.

https://doi.org/10.1182/blood-2019-131324

Published: 2019

Journal Articles

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

Scott Kristian Jew, BS, Tiffany Chang, BS, Sean Elliott Bujarski, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Tahmineh Safaie, Mingjie Li, BS, Eric Sanchez, BA, Cathy S. Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4393.

https://doi.org/10.1182/blood-2019-132013

Published: 2019

Journal Articles

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Camilia M. Soof, BS, Sean Bujarski, BA, Nicole Ng, Jasmin Cao, BS, Tara Hekmati, BS, Edward J Tanenbaum, BS, Brian Zahab, Cathy S. Wang, BS, George Y Tang, PhD, Ning Xu, PhD, James R Berenson, MD

Blood (2018) 132 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2018-99-119099

Published: 2018

Journal Articles

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Sean Bujarski, BA, Camilia Soof, BS, Mingjie Li, BS, Cathy S. Wang, BS, Eric Sanchez, BA, Marsiye Emamy-Sadr, Regina Swift, Kian Rahbari, Saurabh Patil, BS, Tanya M. Spektor, PhD, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2018) 132 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2018-99-119190

Published: 2018

Journal Articles

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clare Sun, MD, Camilia Soof, BS, Alankrita Taneja, MD, Sarah E. M. Herman, PhD, Erika Cook, BA, Kyle Udd, BA, Haiming Chen, MD PhD, Eric Sanchez, BA, Xin Tian, PhD, Inhye E. Ahn, MD, James R Berenson, MD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4031.

https://doi.org/10.1182/blood.V130.Suppl_1.4031.4031

Published: 2017

Journal Articles

Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Camilia Soof, BS, Saurabh Patil, BS, Kyle Udd, BA, Mizi Zhou, MS, Tara Hekmati, BS, Emily Y Wang, Edward J Tanenbaum, BS, Remy Schlossberg, Moryel A Yashar, BS, Cathy S Wang, BS, George Y Tang, PhD, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 4413.

https://doi.org/10.1182/blood.V130.Suppl_1.4413.4413

Published: 2017

Journal Articles

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 4371.

https://doi.org/10.1182/blood.V130.Suppl_1.4371.4371

Published: 2017

Journal Articles

Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the Lagκ-1A Multiple Myeloma Xenograft Model

Eric Sanchez, BA, Mingjie Li, BS, Cathy S Wang, BS, Edward J Tanenbaum, BS, Saurabh Patil, BS, Camilia Soof, BS, Tara Hekmati, BS, Remy E Schlossberg, BS, Moryel A Yashar, BS, Autumn L Porter, BS, George Y Tang, PhD, Haiming Chen, MD PhD, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 5393.

https://doi.org/10.1182/blood.V130.Suppl_1.5393.5393

Published: 2017

Journal Articles

Effects of the Gamma Secretase Inhibitors (GSI) Dapt (GSI-IX) and LSN424354 on Gene Expression and Shedding of Bcma from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells

Blood (2017) 130 (Supplement 1): 5390.

https://doi.org/10.1182/blood.V130.Suppl_1.5390.5390

Published: 2017

Journal Articles

Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti-Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo

Eric Sanchez, BA, Mingjie Li, BS, Cathy S Wang, BS, Puja Mehta, BS, George Tang, PhD, Haiming Chen, MD PhD, James Berenson, MD

Blood (2016) 128 (22): 3297.

https://doi.org/10.1182/blood.V128.22.3297.3297

Published: 2016

NARROW

Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity

Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-Cells By Upregulating IFNγ and Gzmb

The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients

Evaluation of Repotrectinib's Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo

Dominant Expression of PVRIG and TIGIT Inhibitory Pathways in Bone Marrow of Multiple Myeloma Patients

Anti-Myeloma Effects of Panobinostat in Combination with Duvelisib

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the Lagκ-1A Multiple Myeloma Xenograft Model

Effects of the Gamma Secretase Inhibitors (GSI) Dapt (GSI-IX) and LSN424354 on Gene Expression and Shedding of Bcma from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells

Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti-Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only